https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-onureg-azacitidine-tablets-acute-myeloid-leukemia?utm_campaign=Onureg%20-%20azacitidine%20tablets%209-1-2020&utm_medium=email&utm_source=Eloqua&elqTrackId=48e156917e6b45cf966618381bd71caf&elq=f244bfa055804f53a0d713c29b58c2f7&elqaid=14066&elqat=1&elqCampaignId=12073

FDA approves Onureg (azacitidine tablets) for acute myeloid leukemia

On September 1, 2020, the Food and Drug Administration approved azacitidine tablets (ONUREG®, Celgene Corporation) for continued treatment of patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. More information.